After a midstage trial showed no benefit from adding ELX-02 (exaluren) to Kalydeco (ivacaftor, Vertex Pharmaceuticals Inc.) for certain cystic fibrosis (CF) patients, Eloxx Pharmaceuticals Inc. said it will discuss next steps for the program, its lead candidate, with the trial's sponsor, the CF Foundation. A proof-of-concept trial for EXL-02 in the rare kidney disease Alport syndrome will start later this year, the company said.
Previous research has demonstrated that the expression of the calcium-activated potassium channel (Kca 3.1) is higher in patients with idiopathic pulmonary fibrosis (IPF), and that genetic and pharmacological inhibition of Kca3.1 was able to prevent or attenuate fibrosis.
Bridge Biotherapeutics Inc. recently reported data for BBT-209, an endogenous G protein-coupled receptor 19 (GPCR19) agonist under development for the treatment of idiopathic pulmonary fibrosis (IPF).
It is known that dendritic cells and innate lymphoid cells type 2 (ILC2) play key roles in allergen sensitization, and humoral factors such as complement C3a and complement C5a are highly involved in the development and severity of asthma through the binding to their receptors C3AR1 and complement C5a receptor 1 (C5AR1), respectively.
The Massachusetts Institute of Technology (MIT) has developed collagen mimetic peptides for PET imaging to detect idiopathic pulmonary fibrosis (IPF), with [68Ga]DOTA-CMP showing selective identification of fibrotic collagen in vivo.
Lee’s Pharmaceutical (HK) Ltd. and its affiliate, Zhaoke Pharmaceutical (Hefei) Co. Ltd., expanded their rights to lucinactant Surfaxin, lyophilized lucinactant Surfaxin LS and Aerosurf from Windtree Therapeutics Inc. in a $78.9 million global license deal to develop and commercialize the candidates for the treatment of preterm infants with respiratory distress syndrome and other potential indications.
Japan’s Healios K.K. is in discussions with Japan’s Pharmaceutical and Medical Devices Agenc about the regulatory path forward for its Multistem somatic stem cell products, for which it conducted phase II/III trials in ischemic stroke and a phase II trial in acute respiratory distress syndrome.
A metabolite derived from the airway microbiome, indole-3-acetic acid (IAA), could become a potential therapeutic candidate for chronic obstructive pulmonary disease (COPD). Researchers at South China Normal University (SCNU) have shown how IAA prevents lung function decline by reducing inflammation, apoptosis and emphysema through IL-22 in the interaction between macrophages and alveolar epithelial cells.
Japan’s Healios K.K. is in discussions with Japan’s Pharmaceutical and Medical Devices Agenc about the regulatory path forward for its Multistem somatic stem cell products, for which it conducted phase II/III trials in ischemic stroke and a phase II trial in acute respiratory distress syndrome.
RSS
